Zoetis Inc. (ZTS) Stock Price & How to Invest

Zoetis (ZTS) is the world's largest animal health company, developing and selling medicines, vaccines, diagnostics, and other products for both companion animals (pets like dogs and cats) and livestock (cattle, swine, poultry, and fish). Spun out of Pfizer in 2013, it holds leading positions across dermatology, parasiticides, pain, vaccines, and other categories, with well-known franchises such as Apoquel and Cytopoint for pet itch and allergic skin conditions, the Simparica line of parasiticides, and Librela for osteoarthritis pain in dogs. Companion animal products, driven by the long-run humanization of pets and rising spending on their care, have become the larger and faster-growing part of the business, while livestock provides a more staple, protein-demand-linked base. Zoetis sells through veterinarians in the United States and internationally, invests heavily in research and development to sustain its innovation pipeline, and benefits from patents, brand loyalty, and deep vet relationships. Headquartered in Parsippany, New Jersey, it is widely viewed as a defensive-growth leader on the structural trend of people spending more on animal health, though it faces cyclical pet-visit softness, pricing pressure, and rising competition.

Zoetis faces near-term pressure from softer veterinary visit volumes and increased price sensitivity among pet owners, which have weighed on its companion-animal business and prompted trimmed guidance. Competition is intensifying, including newer entrants and generics in key dermatology and parasiticide categories, and patent expirations can erode pricing over time. A large share of revenue comes from outside the United States, exposing it to currency swings and international regulatory and pricing risk. Livestock demand is tied to protein consumption, herd sizes, and disease outbreaks. As a premium-valued, high-quality name, the stock can carry an elevated multiple that leaves it vulnerable to de-rating if growth disappoints. It is a growth-oriented holding, not a deep-value or high-yield income stock.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Zoetis Inc.'s investor relations page or your broker.

• Revenue (2026 guidance): ~$9.7 billion to $10.0 billion
• Q1 2026 revenue: ~$2.3 billion, up ~3% year over year
• Adjusted EPS (2026 guidance): ~$6.85 to $7.00
• Business mix: companion animal (larger, faster-growing) plus livestock
• Key franchises: Apoquel, Cytopoint, Simparica line, Librela, vaccines, diagnostics
• Geographic mix: United States plus large international segment
• Growth profile: mid-single-digit organic operational growth targeted for 2026
• Valuation style: premium multiple typical of a high-quality animal-health leader

Zoetis is valued as a high-quality, defensive-growth compounder, so it often trades at a premium price-to-earnings multiple relative to the broad market. In early 2026 it trimmed full-year guidance, citing softer pet-visit trends, price-sensitive pet owners, and competition, which pressured the stock. Livestock and international growth partly offset soft US companion-animal demand. Figures are approximate and change with each quarter and with currency movements; verify current numbers before relying on them.

If you want ZTS exposure as part of a larger bundle rather than directly, these ETFs hold it meaningfully. Weights are approximate and refresh quarterly.

There are three common ways to get ZTS exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it (MOO), which spreads the position across many companies. Or build it into a focused thematic basket, so ZTS sits alongside other stocks that express the same thesis.

Walnut takes the basket route. Describe a thesis where ZTS fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

Zoetis (ZTS) is the global leader in animal health, with a diversified portfolio spanning companion-animal and livestock medicines, vaccines, and diagnostics, and marquee franchises in dermatology and parasiticides. The long-run humanization of pets and rising animal-health spending give it a durable, defensive-growth demand story, but soft veterinary visits, price sensitivity among pet owners, and intensifying competition can pressure growth. In a portfolio it behaves as a high-quality, relatively defensive growth holding rather than a deep-value or cyclical bet.

Whether ZTS is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is ZTS a buy?, and where the stock could go from here in the ZTS stock forecast.

For income investors, whether ZTS pays a dividend and how the payout looks is covered in does ZTS pay a dividend?